NOV 17, 2015 01:34 PM PST

Mimicking Antibodies Presents Opportunity for HIV Vaccine

WRITTEN BY: Kara Marker
Extensive scrutinizing of the broadly neutralizing antibodies produced by individuals several years into an HIV infection provided invaluable insight into the best target for HIV vaccines. Scientists from the Scripps Research Institute (TSRI) have identified a potential weak spot on the surface of the HIV virus, and they are ready to test vaccine candidates in animal models. 

The TSRI team found four antibodies that targeted the HIV V2 apex, an "attractive target" for vaccines since antibodies recognizing this site are found in 20-30 percent of HIV-infected people who develop broadly neutralizing antibodies (Immunity). In addition, a whopping 90 percent of HIV strains produce this targetable protein, including HIV strains that infect other species. The V2 apex is an effective target for vaccine development since the proteins in this region help stabilize the HIV virus.

By duplicating and engineering the molecular structure of the targeted HIV proteins in the lab, TSRI scientists are able to create vaccines that boost the effect of broadly neutralizing antibodies in HIV-infected people that have already developed antibodies, and introduce the effect to infected people who have not. 

"This study is an example of how we can learn from natural infection and translate that information into vaccine development," said Raiees Andrabi, a TSRI Research Associate. 

Indeed, the TSRI team will potentially be able to give the immune system a microscopic nudge to develop the proper antibodies in response to an HIV infection. 

The last piece of the puzzle while searching for the best way to neutralize HIV virus was found in the specific characteristics of two of the four antibodies found by the team that target the V2 apex. Unlike normal antibodies initially produced by B lymphocytes that need to specialize from their precursor form before finding their target, these two antibodies are able to bind to their target in their original form. Scientists from TSRI believe this quality means all HIV patients receiving vaccines made from this new technology will be able to mount the proper immune response to fight off an HIV infection. 

Check out the following video to learn more about how broadly neutralizing antibodies can be used to fight HIV infections.
Source: TSRI
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 16, 2018
Immunology
JUL 16, 2018
T cells and the Need for Speed
A recent study has shown that T cell receptors are dispersed across the T cell surface, as opposed to clustered, to allow for a rapid immune reaction....
JUL 22, 2018
Cell & Molecular Biology
JUL 22, 2018
Using Nanosubmarines to Fight Tumors and Headaches
Researchers are getting closer to creating targeted therapies that are delivered directly where needed....
AUG 06, 2018
Immunology
AUG 06, 2018
Maternal Dengue Immunity Protects Against Infant Zika Infection
Maternal Dengue immunity produces CD8+ T cells that protect against fetal Zika infection preventing zika-related malformations....
AUG 15, 2018
Immunology
AUG 15, 2018
Therapeutic Macrophages Improve Rare Lung Disorder
The use of therapeutic macrophage transplantation in mice showed great improvement in rare lung disorder caused by deficient macrophages....
AUG 27, 2018
Immunology
AUG 27, 2018
Undiscovered Tunnels from Bone Marrow To Brain
Newly discovered tunnels connect bone marrow of the skull directly to lining of the brain to allow for quick access of immune cells to brain damaged tissues....
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
Loading Comments...